This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
Sepsis	Leukocyte cell-derived chemotaxin 2 (LECT2)	<p><i>In vitro</i> and mouse studies suggest LECT2 could help treat sepsis. In a mouse model of bacterial-induced sepsis, plasma levels of Lect2 were lower than those in healthy mice. In three different mouse models of sepsis, recombinant mouse Lect2 increased survival compared with saline when administered before or during sepsis. In mouse macrophages, Lect2 increased phagocytosis and bacterial clearance compared with saline control. Next steps include pharmacokinetic and toxicology testing.</p> <p>SciBX 6(2); doi:10.1038/scibx.2013.37 Published online Jan. 17, 2013</p>	Patent application filed in China for use of LECT2 in sepsis; unavailable for licensing	<p>Lu, X.-J. <i>et al. J. Exp. Med.</i>; published online Dec. 17, 2012; doi:10.1084/jem.20121466 Contact: Jiong Chen, Ningbo University, Ningbo, China e-mail: jchen1975@163.com</p>